A concerted effort to sequence matched primary and metastatic tumours is vastly improving our ability to understand metastasis in humans. Compelling evidence has emerged that supports 40 the existence of diverse and surprising metastatic patterns. Enhancing these efforts is a new class of algorithms that facilitate high-resolution subclonal modelling of metastatic spread. Here we summarise how subclonal models of metastasis are influencing the metastatic paradigm.
Introduction

45
For the vast majority of patients that die from solid malignancies, lethality can be directly traced to the propensity of their tumour cells to metastasize. Paget's seminal seed and soil hypothesis proposed that the colonization of distant sites by primary seed tumour cells is dependent on a compatible environment in the secondary soil site (1) . Developments of this central idea over the years has led to the prevailing view that metastases are founded by rare single cells that 50 escape from the primary site. A key advantage of this view is that it provides an explanation for the relative rarity of clinical metastasis formation in the general cancer population.
A body of evidence has subsequently accumulated that supports this model of tumour dissemination. Some of the early works include a study of spontaneously arising lung 55 metastases in mouse models of melanoma, where cells uniquely tagged with random irradiation induced karyotypic markers unequivocally indicated that metastases originated from a single progenitor cell (2) . Follow-on experiments showed that when mixtures of two distinct melanoma cell lines were injected intravenously, subsequent lung metastases were derived from only one line and not admixtures of the two cell lines (3) . 60
More recently, models of human metastasis have been updated, especially with regard to timing of spread (4) . Largely responsible for this shift is the application of next-generation sequencing to matched primary and metastatic samples. By identifying sets of shared and private mutations, sample relatedness can be observed and an approximate evolutionary relationship determined. 65 Studies of human colorectal cancer (5) , pancreatic cancer (6), melanoma (7) and neuroblastoma (8) have shown that spread can occur late in the evolution of the primary disease, revealing a linear evolutionary relationship between primary and metastasis. Conversely, in renal cancer (9), metastatic progression has been shown to occur early, with both primary tumour and metastasis having private mutations and thus evolving in parallel. 70 However, follow-up studies in pancreatic (10) and other cancers (11) show examples of both early and late spread, suggesting that timing patterns are not necessarily tumour specific.
Studies across multiple metastases from the same patient have also revealed that asynchronous spread can occur from primary to multiple distant metastatic sites in colorectal 75 cancer (11) as well as seeding from metastatic to secondary metastatic site in a cascading manner in prostate cancer (12) , ovarian cancer (13) and pancreatic cancer (10).
One limitation of these studies is that the clonal composition of each sample is determined using the presence or absence of private and shared mutations. This type of modelling does not allow 80 estimation of clonal frequencies -vital for accurate evolutionary reconstruction and identification of more than two clones per sample. In an attempt to adopt a more detailed modelling strategy, algorithms have been developed that model the clonal composition within a tumour using mutation variant allele frequencies. These algorithms have vastly improved our ability to model and understand metastatic spread. The first use of such an algorithm appeared in a study of 85 primary breast cancers where it was used to accurately identify the clonal makeup of a tumour and infer the evolutionary history of its clones (genetically distinct populations of tumour cells) (14). Since then, a rapidly developing field has emerged that uses high-coverage exome, capture, amplicon and/or whole-genome tumour sequence data to trace clone lineages and infer phylogenetic relationships within and between lesions from individual patients (15, 16) . 90
A subset of recent studies have used these algorithms to infer the evolutionary relationship of clones in matched primary and metastatic samples (17-26), revealing patterns of metastasis only observable using this type of quantitative analysis. A recent review has outlined the implications of these studies on treatment, including a summary of the potential underlying 95 genetic determinants of spread (27). Here we focus specifically on how subclonal modelling of multiple samples from the same individual has shaped our understanding of metastasis in humans.
100
Subclonal modelling of metastasis
By comparing the constituent subclonal mutations between pairs of primary and metastatic samples it is possible to derive the ancestral relationships between tumour clones rather than between tumour samples. This type of modelling has allowed confirmation of existing patterns of metastasismetastasic spread at increased (subclonal) resolution, and has yielded new insights 105 into the patterns and timing of tumour cell spread which we articulate below.
Timing of spread
Seeding from an ancestral clone early during disease development (Figure 1a ), results in a branched evolution pattern, where primary and metastasis evolve in a "parallel" manner (28) . 110
This has been shown at subclonal resolution in two lung cancer cases (22), two glioblastoma cases (26) , one ovarian case (17), seven prostate cases (18, 29) , as well as in mouse models, where evolutionary analysis of skin cancer demonstrated that the majority of tumours adopt a parallel mode of evolution (30) . Much debate exists, however, whether particular tumour types have a dominant mode of evolution in humans. Spread occurring late in the evolution of the 115 primary tumour in a linear fashion ( Figure 1b ) has been observed in one oral cancer case (25), eight melanoma cases (24), and four glioblastoma cases (in these cases from residual tumour cells) (26) . While sample sizes across these studies are not yet sufficient to determine whether certain tumour types are enriched for late or early spread, examples of both have been seen in a study of eighty-two patients with brain metastases originating from various primaries (23), as 120 well as across eleven cases of head and neck cancer (19) .
Seed composition
All tumour types studied at subclonal resolution mentioned in this review showed at least one example of monoclonal seeding where a single clone escapes the primary to found a metastatic 125 deposit ( Figure 1c ).
New data in mouse models of cancer metastasis have challenged the predominant monoclonal model of how metastases are constituted positing that some metastases are comprised of mixtures of distinct tumour clones seeded in a polyclonal manner (31-33). Furthermore, it has 130 also been argued that clones present in polyclonal mixtures are not necessarily indifferent to one another, but may actually cooperate to seed a secondary lesion, suggesting that mutual interclonal cooperation between distinct clones exists (34) . The evidence for such oncogenic cooperation in different model systems has recently been extensively covered in an excellent review (35). 135
The key distinguishing feature required to confirm the existence of polyclonal seeding in bulk sequencing of human samples is the presence of subclonal clusters of mutations across multiple tumours from distinct locations. A mutation is considered subclonal if it appears in only a fraction of the tumour cells in a sample. Sets of mutations appearing subclonally in two or 140 more metastases can arise under two potential scenarios: (1) the same sets of mutations occur independently in each sample; (2) two distinct founder cells containing the sets of mutations spread to each location together. While convergent evolution could give weight to scenario 1, it is extremely unlikely statistically given the sizeable sets of subclonal mutations observed in the studies discussed here. Therefore, scenario 2 can be the only real explanation for these 145 subclonal clusters. It is this reasoning that has allowed the determination of the existence of polyclonal seeding in humans.
Many of the studies discussed here have gone a step beyond subclonal clustering and inferred the evolutionary relationship between clones. This process facilitates finer understanding of 150 polyclonal seeding and begins to help us determine if the polyclonal spread occurs synchronously with both cells transiting in unison, or asynchronously with multiple waves of spread to the same location. Although evidence is yet to accumulate to unequivocally determine synchronicity, the clonal evolution trees determined from multiple studies tend to favour one or the other. 155
Synchronous polyclonal seeding is a plausible explanation for the patterns of spread observed in six separate studies across five tumour types: oral, breast, glioblastoma, melanoma and prostate (Figure 1d ). In these studies, similar mixes of clones were detected in multiple samples from the same individual: Wood et al. reconstructed the clonal evolution of a matched oral 160 primary and metastasis in patient PG030, showing that the same mix of clones was present in both samples (25); Murtaza et al observed two subclonal mutation clusters present at varying frequencies across five distant metastatic sites from a single breast cancer patient (21); two patients (C and E) showed evidence of polyclonal seeding in a study of melanoma (24); two cases of glioblastoma revealed clusters of mutations present at subclonal fractions in both 165 primary and recurrent disease (26) and, two separate studies into prostate cancer revealed multiple cases of polyclonal seeding (18, 29) . While it is feasible that the mix of clones observed across these cases could have arisen asynchronously, evidence seen in studies of circulating tumour cell clusters lends weight to a synchronous model of spread: for example, a recent study of clusters of circulating tumour cells versus single cells showed that cell clusters had up to fold increased metastatic potential compared to single cells (36) . Interestingly, however, in a study of 86 brain metastasis cases arising from various primary tumours, no evidence of polyclonal seeding was found (23) even though the authors explicitly searched for it. These differences could be attributed to the metastatic niche, whereby the blood-brain barrier prevented clusters of cells transiting but allowed single cell spread. This suggests that the ability 175 for multiple clones to colonise a site could be heavily dependent on the metastatic niche.
Despite the preference for a synchronous model of spread, asynchronous polyclonal seeding has been shown to be a more likely explanation for at least two patients from the aforementioned prostate studies (Figure 1d ) (18, 29) . In patient 177 from Hong et al. (29) , a 180 combination of unusual mutant allele frequency patterns combined with structural variant allele frequencies lead to the most likely explanation of the polyclonal makeup of a metastasis being an early spread from the primary tumour, followed by a late spread of a further evolved clone ( Figure 1c ). In patient A32 from Gundem et al., a left supraclavicular lymph node was seeded twice from the primary tumour. In the first wave of metastatic seeding, all 4 of the metastatic 185 sites in this patient were seeded with a particular clone, however in a subsequent round of spread, a second distinct metastasizing clone spread to the left supraclavicular lymph node only and not the other three metastatic sites. These findings raise important questions as to whether some tumour clones act as pathfinders' colonizing distant sites, which then act as beacons to attract subsequent waves of metastatic colonization in the nascent metastatic niche. Properties 190 of the metastatic niche itself are also likely to contribute to metastatic subclonal seeding and expansion, as evidenced by patient A32. They also clearly suggest that for some patients, at least, removal of the primary tumour even after distant metastases have already been detected may still be clinically warranted as the primary tumour may continue to serve as an incubator of further metastatic tumour cell dissemination. This concept is now supported by a growing body 195 of clinical evidence suggesting that treatment of primary tumours in patients with synchronous metastases can provide clinical benefits, including improvements in overall survival (37) (38) (39) (40) . Further along these lines, one could postulate that polyclonal seeding may occur more often at terminal disease stages where natural defence mechanisms are strained, facilitating easier colonization by multiple tumour clones. 200 Seed source Subclonal modelling of multiregional of multiregional primary prostate tumour samples, allowed Hong et al. (29) to precisely pinpoint the clone that gave rise to a distant metastasis (Figure 1d) . Furthermore, by defining each clone in the primary, they were able to interrogate its presence in 205 circulating tumour DNA and found that in addition to the (expected) detection of metastatic clones, clones (presumed) exclusive to the primary tumour were also detected, despite the primary tumour being removed two years prior. These clones had not seeded any clinically obvious metastases, strongly implying that all clones had colonised distant sites, some occult. 210
As well as seeding from the primary, cells from one metastasis can seed another metastasis, resulting in what is known as an evolutionary cascade (Figure 1d ). This phenomenon has been seen at subclonal resolution from lymph node to distant metastasis in mouse models of skin cancer (30) , single cases of human breast cancer (21) and melanoma (24), and multiple prostate cases (18, 29) . In one of these prostate cases, cross-metastatic site seeding appeared 215 to occur directly in response to the onset of targeted treatment, with marked remodelling of the original subclonal composition at an iliac crest metastatic site within 12 weeks of the patient starting androgen deprivation therapy. Similar subclonal remodelling has also been shown in response to chemotherapy in ovarian cancer (17) and leukemia (41) . 220
Detecting polyclonal seeding Patterns of polyclonal seeding can only be detected using algorithms that identify the subclonal makeup of multiple tumour samples from a given patient (42) (43) (44) (45) (46) . While there are a number of different computational techniques for inferring subclonal structure, the majority of studies covered in this review have used a statistical clustering algorithm known as a Bayesian Dirichlet 225
Mixture Model. Therefore, to illustrate how polyclonal seeding is detected, we adapt an example from Gundem et al. (18) , see Figure 2 . We look at two samples from patient A22, a bladder metastasis (G) and a pelvic lymph node metastasis (H). Firstly, using copy-number, tumour purity, and tumour ploidy, the mutant allele fraction of each mutation is converted to the fraction of tumour cells harbouring the mutation, represented as black dots in pigeon-hole principle (14) can then be used reconstruct the most likely clonal evolution tree (Fig.  2b) . As the purple cluster is present at subclonal frequencies in both samples, both cells from this clone and cells from the ancestral clone (dark blue circle) must have founded the metastatic site G in a polyclonal manner. The resulting clonal makeup can be represented by colour coded nested ovals reflecting the evolutionary relationship between clones (Fig. 2c , white space 245 represents normal cell admixture). Finally an overall schematic of the clonal spread can be derived (Fig. 2d) .
Discussion
250
The application of whole-genome sequencing and new computational methods to multiple metastatic samples has enabled exciting insights into the process of metastatic seeding, the presence of polyclonal seeding being the most significant. Some headway has been made through animal models of breast cancer, with a recent study showing that clusters of tumour cells have a much higher capacity to induce metastasis 260 formation, despite being present at much lower frequency than single cells (36) . Furthermore, tumour cell clusters did not form in the blood but rather appeared to form within the site of tumour cell inoculation. Another important question is whether and to what extent specific clones may be involved in establishing pre-metastatic niches conducive to subsequent waves of tumour cell inoculation. Evidence in favour of this is the observed extracellular vesicles secreted 265 by tumour cells that can be sequestered by bone-marrow derived cells, enhancing their capacity to form a metastatic niche (47) (48) (49) . Following-on, specific clones might also be able to modify the metastatic potential of surrounding less metastatic clones through transfer of metastatic extracellular vesicles, as has been recently demonstrated in animal models of breast cancer (50) . Further application of subclonal modelling to this question in humans is likely to yield 270 greater insight.
The polyclonal seeding observed in multiple sites across the cases discussed in this review may be indicative of intimate crosstalk occurring between metastatic clones and suggests that targeted disruption of these interactions might be productive in obstructing metastasis formation. 275
Certain patterns of metastasis may be targeted by particular treatment regimes. However, these insights are currently limited by the availability of samples, so predicting which pattern is likely to occur in a given tumour subtype is not yet feasible. Further studies incorporating the subclonal analysis of multiple primary and multiple metastases from individual patients are required to not only answer fundamental questions as to how tumour cells metastasize but also provide insights 280 in to how this process may be disrupted. 
